AstraZeneca

Request for Proposal (RFP) for an Independent Scientific Sponsorship Grant focused on healthcare quality improvement

Therapeutic Area:	Hypertension
Focus:	AstraZeneca is interested in receiving proposals seeking funding for healthcare quality improvement (QI) initiatives designed to optimize the identification, diagnosis and treatment of uncontrolled or resistant hypertension (patients with blood pressure that is not at goal despite 2 or more antihypertensive medications) within a clinical setting.
Guidance:	Funding is available to off-set expenses for a Quality Improvement Initiative. Proposals must contain a strong educational component for clinicians, including evidence of impact on the project and outcome metrics report. The grant proposal should include: - Needs assessment to evaluate existing gaps, barriers and opportunities in identification, diagnosis and treatment of uncontrolled or resistant hypertension patients. - What are you trying to accomplish? Include a clearly defined aim for the QI initiative. - What change can you make that will result in improvement? Include an action plan for the initiative, with how education will be developed and disseminated as part of the plan. - How will you know that the proposed initiative or change is an improvement? Include a plan to measure the success of the initiative. - Is the change sustainable? Include a plan for how you will sustain the improvements, so they are integrated into routine practice. - How will you share learnings to drive awareness and adoption of the initiative?
Recommended Audience:	Clinical setting: Cardiology, Internal Medicine, Primary Care Clinical role: Physicians, Advanced Practice Providers, Trainees (residents, fellows), Nurses, Pharmacists, Medical Assistants.

	Applications from health care organizations, associations, academic institutions, and hospitals will be prioritized.
Out-of-Scope:	Scientific Research Projects, Implementation Science research studies, Implementation Science and Precision Medicine Projects
Program Anticipated Start Date:	February 1, 2027 through August 1, 2027
Final Grant Decision:	Grants will be reviewed for consideration and approved on a rolling basis starting January 5, 2027
Support request:	Applications requesting up to $50K
RFP reference code:	CGA_Hypertension_QI_2027
Submission Information & links:	grants@astrazeneca.com (email communication) www.astrazenecagrants.com Donna Maier, PhD, Associate Director, Medical Education and Grants Office, donna.maier@astrazeneca.com

AstraZeneca, Medical Education Grants Office (MEGO):

AstraZeneca is committed to supporting quality independent medical education and scientific sponsorships that meets an educational need by providing information to healthcare professionals to improve patient care and outcomes. We support scientific or educational initiatives designed to educate and support the efforts of healthcare professionals to broaden patient knowledge and awareness of disease states and treatment. The initiative must be educational and non-promotional in nature and planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities. Our grant support is focused within areas of high unmet need that overlap with our medical areas of interest. For more information, please visit https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office.html